Safety, tolerability and clinical effects of BC007 (Rovunaptabin) on fatigue and quality of life in patients with post-COVID syndrome (reCOVer): a prospective, exploratory, randomised, placebo-controlled, double-blind, crossover phase IIa clinical trial
Bettina Hohberger, Marion Ganslmayer, Thomas Harrer, Friedrich Kruse, Stefanie Maas, Tobias Borst, Ralph Heimke-Brinck, Andreas Stog, Thomas Knauer, Eva Rühl, Victoria Zeisberg, Adam Skornia, Alexander Bartsch, Armin Ströbel, Monika Wytopil, Carolin Merkel, Sophia Hofmann, Katja G. Schmidt, Petra Lakatos, Julia Schottenhamml, Martin Herrmann, Christian Mardin, Jürgen Rech
medRxiv 2024.12.13.24318856; doi: https://doi.org/10.1101/2024.12.13.24318856